Omega-3.
The essential fats the body cannot make — and the most studied supplement in the world?
Omega-3 fatty acids — EPA and DHA — are essential nutrients the human body cannot synthesize: they must arrive in the diet, from fish, from algae, or from a capsule. They integrate into every cell membrane, become the raw material for anti-inflammatory signaling molecules, and modulate triglycerides, blood vessels, and nerve tissue. It is the most-trialed supplement in existence — and the field's honest lesson: the effect depends on the dose, the formulation, and the population. The landmark event trial (REDUCE-IT) used prescription purified EPA at 4 g and cut events 25%; a mixed-formulation trial at the same dose came back null; retail doses are a different exposure entirely. This page teaches the fats, the evidence, and the reading skills the aisle never provides.
EPA & DHA
Two long-chain polyunsaturated fatty acids from marine sources: EPA (eicosapentaenoic acid) — the anti-inflammatory signaling molecule, and DHA (docosahexaenoic acid) — the structural fat of brain and retina. The body can convert plant ALA (~5–8% efficiency) but cannot make them from scratch. Fish don't make them either — algae do; fish are the middlemen.
EPA and DHA embed in every cell membrane — altering fluidity, receptor function, and the lipid raft microdomains where signaling happens.
The raw material for resolvins and protectins — specialized molecules that actively END inflammation rather than merely suppressing it. Omega-3s don't just reduce inflammation; they help resolve it.
Dose-dependent and reliable: 2–4 g daily reduces triglycerides 20–30% — the best-established supplemental effect in the cardiovascular literature.
The REDUCE-IT story — 25% event reduction with prescription purified EPA at 4 g in high-risk statin-treated patients. The strongest result a supplement-class molecule has posted; formulation- and dose-dependent.
DHA is the dominant structural fat of the brain's gray matter and the retina — the neurologic half of the pair, from our depression page's EPA trials to infant-development science.
Pooled analyses of adjunct trials find antidepressant benefit for EPA-DOMINANT formulations — the ratio matters, and our depression page teaches it in full.
Omega-3s work by BECOMING the tissue: once in a membrane, EPA and DHA displace arachidonic acid — the omega-6 fat that inflammatory enzymes convert into prostaglandins and leukotrienes — shifting the substrate availability of the entire inflammatory cascade. The deeper action is resolution: resolvins and protectins are actively anti-inflammatory, signaling the immune system that the work is done. This is why omega-3s' effects are systemic and slow — they work by changing what the body is made of, over weeks of consistent intake.
Fish-Oil Softgels
The standard form
TG vs EE
Triglyceride absorbs better
Algal Softgels
The vegan route, DHA-heavy
Liquids & Gummies
Dose math varies — read labels
Triglyceride (TG) Form
The natural form in fish — and the form back-converted from ethyl esters by premium brands. Absorbs ~70% better than EE in head-to-head studies, especially when taken WITHOUT food (with a fat-containing meal, the gap narrows). The form the top pick uses.
Ethyl Ester (EE) Form
The concentrate chemistry that makes high-dose capsules possible — but requires pancreatic digestion before absorption. Cheaper per mg, absorbed adequately WITH fat, poorly without. The form most budget products (and prescription Lovaza) use.
Phospholipid (Krill) & Algal Forms
Krill oil delivers omega-3s in phospholipid form — well-absorbed at lower doses, but EPA+DHA per dollar is the worst in the category. Algal oil is the vegan route — clean sourcing, DHA-dominant profile (check the EPA line for mood purposes). Both are legitimate; neither justifies its premium on absorption alone.
The Formulation Wars — The Field's Defining Lesson
The omega-3 evidence base teaches the sharpest lesson in supplement literacy: the same molecule at the same dose, in a different formulation, in a different population, produces a different result. The two landmark trials: REDUCE-IT (2019) — prescription purified EPA (icosapent ethyl) at 4 g/day in high-risk, statin-treated patients with elevated triglycerides — reduced cardiovascular events by 25%. STRENGTH (2020) — a mixed EPA/DHA formulation at the same 4 g dose, similar population — found nothing.
What differs? Formulation (purified EPA vs. a mix), carrier (mineral oil vs. corn oil placebo), population details — the debate continues, and the honest reading is not 'omega-3s work' or 'omega-3s don't' but: which composition, at what dose, for whom. The retail shelf sits at 300–650 mg actives per serving — a completely different exposure from either trial. The consumer lesson: the aisle quotes REDUCE-IT on labels delivering an eighth of the dose; the informed reader notices, and this page exists to make you one.
- The reliable effect: triglyceride lowering, 20–30% at 2–4 g/day — dose-dependent, replicated, the basis of prescription omega-3 drugs.
- The population effect: event reduction in high-risk statin-treated patients — REDUCE-IT's 25% with prescription EPA; not established at retail doses in the general population.
- The mood effect: adjunct antidepressant benefit for EPA-DOMINANT formulations (≥60% EPA) in pooled analyses — our depression page's Tier 2, ratio-dependent.
- The joint and airway effects: modest and mixed — genuine anti-inflammatory mechanism, modest trial outcomes in osteoarthritis and asthma.
- The honest ceiling: not a statin, not an antidepressant, not an anti-inflammatory drug — an essential nutrient with formulation-dependent effects, adjunct to the prescription tier everywhere it appears in this library.
What It Does NOT Do
The honest negative space — where the aisle's confidence outruns the data:
- It does not prevent cardiovascular events in the general population at retail doses. The large primary-prevention trials of 1 g mixed omega-3 (VITAL and successors) found no significant event reduction — the benefit concentrates in the high-risk, high-triglyceride, high-dose prescription context.
- It does not improve dry eye in most trials. Despite the DHA-in-retina logic, large trials were largely null — an example of mechanism elegance not cashing in.
- It does not prevent dementia or cognitive decline in older adults. The brain is DHA-rich, but supplementation trials in established cognitive aging have been disappointing — the evidence lives in development (infant brains need DHA) more than rescue.
- It does not treat depression alone. EPA-dominant formulas show adjunct benefit added to standard treatment — our depression page grades them Tier 2 adjunct, never replacement.
- It is not dose-free. The AF signal at 1 g+ is the category's honest asterisk: more is not automatically better, and high-dosing belongs in a physician conversation, especially for anyone with atrial fibrillation history or risk.